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Adjunctive use of the superficial femoral vein for
vascular reconstructions
Soma Brahmanandam, MD, MPH,a Daniel Clair, MD,a James Bena, MS,b and
Timur Sarac, MD,a Cleveland, Ohio
Objective:Although the superficial femoral vein (SFV) is an accepted treatment for aortic graft infections, this conduit also
has potential uses in other areas. Herein, we evaluate our experience using the SFV for arterial and venous bypasses and
the arteriovenous (AV) fistula for dialysis access.
Methods: Between 1999 and 2011, 42 patients underwent a bypass or a thigh AV fistula using the SFV (31 arterial, four
central venous, six AV fistulas, and one common carotid-to-vertebral bypass). Indications for arterial bypass included
infected graft (20), critical limb ischemia (nine), and failed bypass (six). Indications for central venous bypass were:
superior vena cava syndrome (two), vessel reconstruction due to tumor encasement (one), and central vein occlusion from
thoracic outlet syndrome (one). All AV fistulas were created after patients sustained bilateral subclavian vein occlusions
from failed upper extremity access. The common carotid-to-vertebral bypass was created due to an occluded vertebral
artery with resultant stroke.
Results:Kaplan-Meier cumulative patency curves were used. The primary patency rates at 30 days, 1 year, and 3 years were
97.4% (95% confidence interval [CI], 92.41-100), 74.6% (95% CI, 57.89-96.23), and 66.4% (95% CI, 47.06-93.53),
respectively. The assisted primary patency rates at 30 days, 1 year, and 3 years were 100% (95% CI, 100-100), 97.1% (95%
CI, 91.54-100), and 89% (95% CI, 74.29-100), respectively. Secondary patency rates at 30 days, 1 year, and 3 years were
100% (95% CI, 100-100), 97.1% (95% CI, 91.54-100), and 89% (95% CI, 74.29-100), respectively. Limb salvage rates
at 30 days, 1 year, and 3 years were 97.3% (95% CI, 92.21-100), 93.6% (95% CI, 78.35-100), and 93.6% (95% CI,
78.35-100), respectively. Survival rates at 30 days, 1 year, and 3 years were 97.6% (95% CI, 92.95-100), 86% (95% CI,
75.3-98.3), and 86% (95% CI, 75.3-98.3), respectively. Follow-up ranged from 1 month to 8.7 years (mean time, 21
months). Complications occurred in 22 patients (52%) and included wound complications (n  19; 45.2%); deep vein
thrombosis (n  1; 2.4%); anastomotic breakdown (n  1; 2.4%); hematoma (n  4; 9.5%); pulmonary embolism (n 
2; 4.8%); and compartment syndrome (n  2; 4.8%).
Conclusions: The SFV is a durable conduit for uses beyond aortic reconstruction and should be considered when the great
saphenous vein is not available or size match is a concern. However, wound complications remain a problem. (J Vasc
Surg 2012;55:1355-62.)
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pThe superficial femoral vein (SFV) has proven to be a
successful arterial conduit in the treatment of arterial insuf-
ficiency and more commonly of prosthetic graft infections.
Schulman et al1-3 demonstrated that the SFV could be used
as an alternate conduit for femoral-popliteal arterial bypass
with patency rates comparable to the great saphenous vein
(GSV). Another common use for the SFV has been in
constructing the neoaortoiliac system to treat prosthetic
aortofemoral graft infections. Studies by Clagett et al4,5
have shown that the neoaortoiliac system is also associated
with excellent patency rates.
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doi:10.1016/j.jvs.2011.11.129Despite the suitability of this conduit, there have been
oncerns for venous morbidity in the donor limb after SFV
arvest. Coburn et al6 found that deep vein harvest was
ssociated with venous stasis edema, occasionally resulting
n phlegmasia and limb loss. Multiple other studies, how-
ver, have demonstrated a low incidence of venous morbid-
ty, which in most cases resolved over time, leaving minimal
o no clinical disability.1,2,4,5,7,8
Given the durability and minimal morbidity of the SFV
onduit in aortic and lower extremity (LE) reconstructions,
e have used the SFV in other areas requiring autogenous
onduits. In this study, we present our 12-year experience
ith the SFV as a conduit for vascular reconstructions,
ncluding nonaortic arterial and venous bypasses and arte-
iovenous (AV) fistula for dialysis access.
ETHODS
This study was approved by our institutional board.
etween 1999 and 2011, 42 patients underwent nonaortic
FV reconstructions. We performed a retrospective review
f the patients’ outcomes, which included morbidity and
ortality, patencies, and limb salvage. We also analyzed the
atients’ demographics, indications for procedures, and
perative details.9
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May 20121356 Brahmanandam et alOur study population underwent 31 LE arterial recon-
structions, four central venous bypasses, six AV fistulas, and
one carotid-to-vertebral bypass (Table I). Indications for
the LE arterial reconstructions included peripheral vascular
disease (claudication, rest pain, and tissue loss), infected
native vessel or graft, failed bypass, or tumor encasing an
artery. Venous reconstructions were performed for superior
vena cava (SVC) syndrome, tumor encasing a vein, and
thoracic outlet syndrome. All fistulas were created for dial-
ysis access, and the carotid-to-vertebral bypass treated a
patient who had a cardiovascular accident secondary to an
occluded vertebral artery. SFV was used in all the above
reconstructions due to the absence or unsuitable nature
(sclerotic or diameter2.5 mm) of the GSV and arm veins.
Generally, the deep vein was harvested if the GSV was
patent on that side to prevent postoperative venous mor-
bidity. For non-LE cases, SFV grafts were harvested from
the leg with the higher ankle-brachial index. For LE recon-
structions, the SFV was harvested mainly from the opera-
tive limb, because it could be done from the same incision.
All LE grafts had inflow from either the iliac or femoral
arteries, and the femoral artery was the most distal outflow
vessel.
Patients who underwent elective surgery had a preop-
erative venous duplex ultrasound of their deep and super-
ficial systems to assess the patency, size, and quality of the
deep veins. For emergent cases, the quality of the deep vein
was evaluated intraoperatively. All SFV conduits were har-
vested through an incisionmedial to the sartorius, and from
just below the level of the common femoral vein and
profunda bifurcation, to the above-knee popliteal vein.
Venous branches were doubly ligated. Once harvested, the
SFV was used in a reversed fashion as a single segment
conduit. Valve lysis was at the discretion of the surgeon and
not routinely documented. An example of one of our SFV
conduits can be seen in Fig 1.
All fistulas were created using a transposition technique
as described by Jackson.10 The SFV was harvested from the
common femoral vein down to the above-knee popliteal
vein. The SFV was ligated and transected distally, tunneled
on the medial anterior thigh, and anastomosed to the
superficial femoral artery in an end-to-side fashion.
Postoperative surveillance was performed on all grafts
Table I. Procedures
Procedure No. (42)
Lower extremity 31
Cross-pelvic fem-fem bpg 10 (23.8%)
Iliofemoral bpg 19 (45.2%)
Fem-fem interposition bpg 2 (4.8%)
Venous 4
Axill/SVC-innominate bpg 3 (7.1%)
Innominate-SVC bpg 1 (2.4%)
Fistulas 6 (14.3%)
Other 1
CCA-vertebral bpg 1 (2.4%)
Axill, Axillary; bpg, bypass; CCA, common carotid artery; Fem-fem, femorausing duplex scan imaging. All patients underwent graft (urveillance and pulse volume recordings at 1 month, every
months for the first year, and every 6 months thereafter.
atients underwent angiography if the ankle-brachial index
ecreased by more than 0.15, or the peak systolic velocity
atio between adjoining segments was greater than four.
herapeutic interventions, such as angioplasty, stent place-
ent, or surgery were performed when appropriate.
Statistical analysis. Categorical factors were de-
cribed using frequencies and percentages, whereas contin-
ous measures were described using means, SDs, medians,
nd ranges, as appropriate. To estimate rates of patency,
imb salvage, and survival, Kaplan-Meier estimates were
alculated overall and by treatment group. Point estimates
or each measure are presented with 95% confidence inter-
als (CIs). Analyses were performed using 9.1 software
SAS Institute, Cary, NC) and R 2.8 software (Vienna,
ustria).
ESULTS
Our study population consisted of 42 patients, of which
2 were men (52.4%) and 20 were women (47.6%) with an
verage age of 62.5  13.2 years. Thirty-two were white
ig 1. Example of superficial femoral vein (SFV) interposition
rafts for a patient who had a tumor encasing her subclavian vein
nd artery.
mergent Infected Redo
(58.1%) 20 (64.5%) 27 (87.1%)
(0%) 0 (0%) 0 (0%)
(0%) 0 (0%) 0 (0%)
(100%) 0 (0%) 0 (0%)
oral bypass grafts; SVC, superior vena cava.E
18
0
0
176.2%) and 10 were black (23.8%). The most prevalent
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Volume 55, Number 5 Brahmanandam et al 1357comorbidities among this group of patients were hyperten-
sion (35; 83.3%), hyperlipidemia (29; 69.0%), and coro-
nary artery disease (23; 54.8%; Table II).
Indications for an LE arterial bypass included: infected
native vessel/graft (20; 64.5%), ischemia (11; 35.5%),
failed bypass (6; 19.3%), and tumor encasement of vessels
(one; 3.2%). Of the LE cases, 18 patients (58.1%) were
emergent and 27 patients (87.1%) underwent redo surgery.
Central venous bypasses were performed for SVC syn-
drome (two; 50.0%), tumor encasement of deep veins (one;
25.0%), and thoracic outlet syndrome (one; 25.0%). All
fistulas were performed for dialysis access. The carotid-to-
vertebral bypass was performed for a cardiovascular acci-
dent secondary to an occluded vertebral artery. Of patients
with an infection, staphylococcus (eight; 40.0%) was the
most common organism cultured, followed by enterococ-
cus (three; 15.0%) and pseudomonas (three; 15.0%). The
remaining six patients had no growth seen on their cultures.
The diameter of SFV grafts evaluated preoperatively in
patients with nonemergent LE was 8.5 mm 1.8 mm (n
13). SFV diameters were not available for the other types of
reconstructions.
Wound problems were themost common complication
across all four categories of procedures. Among patients
who underwent LE procedures, nine (29.0%) had wound
complications in the first 30 days, and an additional four
patients developed late wound problems (total 13; 41.9%).
The specific types of wound complications included two
seromas (groin and harvest site) that were managed conser-
vatively; two infected groin lymphoceles treated with sar-
torius and rectus femoris muscle flaps and wound debride-
ment; seven wound dehiscences (four involving the harvest
site) that were managed conservatively; two wound necro-
ses that were managed with debridement and dressings;
and one nonhealing fasciotomy wound in the harvest limb
treated by improving arterial circulation to that limb
Table II. Demographics and comorbidities (all patients)
No. (42) Percentage
Age 62.5  13.2
Gender (male) 22 52.4
Race
White 32 76.2
African American 10 23.8
BMI 27  5.0
Tobacco 15 35.7
Hypertension 35 83.3
CAD 23 54.8
Diabetes 15 35.7
Hyperlipidemia 29 69.0
COPD 10 23.8
Renal failure 12 28.6
BMI, Body mass index; CAD, coronary artery disease; COPD, chronic
obstructive pulmonary disease.
Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et al.
Recommended standards for reports dealing with lower extremity ischemia:
revised version. J Vasc Surg 1997;26:517-38.(superficial femoral artery/profunda endarterectomies). 9ound complications mainly involved the operative inci-
ion (10 patients) vs the harvest site (three patients). Addi-
ionally, nine of the 13 patients with wound complications
ad a previously infected groin wound. Five patients who
nderwent the other three procedures (venous, fistula, and
ther) had minor wound complications, including dehis-
ence and minimal skin necrosis, managed effectively with
onservative measures; the majority involving the harvest
ite (three of five patients; Table III).
Deep vein thrombosis (DVT) and pulmonary embo-
ism were seen in two patients who underwent LE proce-
ures. Both patients were treated successfully with oral
nticoagulation. The patient with aDVT had undergone an
liofemoral bypass and developed his DVT in the operative
imb, which was also the donor limb (Table III).
Four patients suffered a postoperative hematoma (all of
hom underwent LE bypass) requiring operative evacua-
ion. Causes for hematomas included bleeding side branch
f the SFV graft (n  1) and small arterial bleeders, unre-
ated to the graft (n  3; Table III).
Anastomotic rupture occurred in one patient who had
quamous cell cancer that encased his femoral vessels. He
nderwent resection of the tumor, which included the
emoral artery, followed by femoral artery reconstruction
ith ipsilateral SFV and a rectus femoris muscle flap. Two
eeks after the index procedure, he had necrosis of the
uscle flap, which led to desiccation of the underlying SFV
raft and subsequent blowout in one area of the anastomo-
is. Pressure was then held over the graft for hemostasis
ausing thrombosis. Consequently, the patient underwent
perative thrombectomy and revision of the graft. Ten days
fter this revision, he again developed exsanguinating hem-
rrhage from the graft, requiring both vein graft ligation
nd hip disarticulation (Table III).
Compartment syndrome occurred in two patients. The
rst patient developed a tight anterior compartment intra-
peratively with elevated creatine phosphokinases during
reation of an iliofemoral SFV bypass graft. He underwent
elease of the anterior, lateral, and superficial posterior
ompartments intraoperatively. The second patient devel-
ped compartment syndrome on the first postoperative day
n the calf of the harvest limb, requiring four-compartment
asciotomy. This was performed in both patients due to
eperfusion injury. Both patients convalesced with no fur-
her problems (Table III).
Of patients undergoing fistula creation, one patient had
teal syndrome. This was corrected by performing a distal
evascularization and interval ligation procedure as a fem-
ral above-knee popliteal artery bypass. Subsequently, the
atient had no further issues.
Late venous morbidity, including chronic venous
hanges or venous claudication, was not seen in any of our
atients.
Outcomes. Overall Kaplan-Meier cumulative patency
urves are shown in Fig 2. The primary patency rates at 30
ays, 1 year, and 3 years were 97.4% (95% CI, 92.41-100),
4.6% (95% CI, 57.89-96.23), and 66.4% (95% CI, 47.06-
3.53), respectively. The assisted primary patency rates at
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97.1% (95% CI, 91.54-100), and 89.0% (95% CI, 74.29-
100), respectively. Secondary patency rates at 30 days, 1
year, and 3 years were 100% (95% CI, 100-100), 97.1%
(95% CI, 91.54-100), and 89.0% (95% CI, 74.29-100),
respectively.
The patients who underwent LE procedures had pri-
mary patency rates at 30 days, 1 year, and 3 years of 96.3%
(95% CI, 89.43-100), 88.3% (95% CI, 73.29-100), and
88.3% (95% CI, 73.29-100), respectively. The assisted
primary patency rates at 30 days, 1 year, and 3 years were
100% (95% CI, 100-100), 100% (95% CI, 100-100), and
100% (95% CI, 100-100), respectively. Secondary patency
rates at 30 days, 1 year, and 3 years were 100% (95% CI,
100-100), 100% (95% CI, 100-100), and 100% (95% CI,
Table III. Complications
Complication
All (42) LE (31)
30 Days (%) All (%) 30 Days (%) All (%) 3
Wound
complication 14 (33.3) 19 (45.2) 9 (29.0) 13 (41.9)
DVT 1 (2.4) 1 (2.4) 1 (3.2) 1 (3.2)
Anastomotic
breakdown 1 (2.4) 1 (2.4) 1 (3.2) 1 (3.2)
Hematoma 4 (9.5) 4 (9.5) 4 (9.5) 4 (9.5)
PE 1 (2.4) 2 (4.8) 1 (3.2) 2 (6.5)
Compartment
syndrome 2 (4.8) 2 (4.8) 2 (6.5) 2 (6.5)
DVT, Deep vein thrombosis; LE, lower extremity; PE, pulmonary embolism
Fig 2. Three-year Kaplan-Meier estimates for surviva
patencies for all patients.100-100), respectively (Table IV, Fig 3). 1For patients who underwent venous procedures, pri-
ary patency rates at 30 days, 1 year, and 3 years were 100%
95% CI, 100-100), 50.0% (95% CI, 18.77-100), and
5.0% (95% CI, 4.58-100), respectively. The assisted pri-
ary patency rates at 30 days, 1 year, and 3 years were 100%
95% CI, 100-100), 75.0% (95% CI, 42.59-100), and
0.0% (95% CI, 18.77-100), respectively. Secondary pa-
ency rates at 30 days, 1 year, and 3 years were 100% (95%
I, 100-100), 75.0% (95% CI, 42.59-100), and 50.0%
95% CI, 18.77-100), respectively (Table IV).
For patients who underwent fistula creation, primary
atency rates at 30 days, 1 year, and 3 years were 100% (95%
I, 100-100), not applicable (N/A), and N/A, respec-
ively. The assisted primary patency rates at 30 days, 1 year,
nd 3 years were 100% (95% CI, 100-100), 100% (95% CI,
enous (4) Fistulas (6) Other (1)
ys (%) All (%) 30 Days (%) All (%) 30 Days (%) All (%)
.0) 2 (50.0) 2 (33.3) 3 (50.0) 1 (100) 1 (100)
0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
b salvage, primary, assisted primary, and secondaryV
0 Da
2 (50
0 (0.
0 (0.
0 (0.
0 (0.
0 (0.l, lim00-100), and 100% (95% CI, 100-100), respectively. Sec-
i
i
e
ts are a
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100% (95% CI, 100-100), 100% (95% CI, 100-100), and
100% (95% CI, 100-100), respectively (Table IV).
The patient who underwent a common carotid artery
Table IV. Kaplan-Meier estimates of all outcomes
Procedures Primary patency
Assisted primary
patency
All
1 month 97.4 (92.41-100) 100 (100-100)
12 months 74.6 (57.89-96.23) 97.1 (91.54-100)
36 months 66.4 (47.06-93.53) 89.0 (74.29-100)
LE
1 month 96.3 (89.43-100) 100 (100-100)
12 months 88.3 (73.29-100) 100 (100-100)
36 months 88.3 (73.29-100) 100 (100-100)
Venous
1 month 100 (100-100) 100 (100-100)
12 months 50.0 (18.77-100) 75.0 (42.59-100)
36 months 25.0 (4.58-100) 50.0 (18.77-100)
Fistulas
1 month 100 (100-100) 100 (100-100)
12 months 0a (0-0) 100 (100-100)
36 months 0a (0-0) 100 (100-100)
Other
1 month 100 (100-100) 100 (100-100)
12 months N/Ab N/Ab
36 months N/A N/A
LE, Lower extremity; N/A, not applicable.
aA patency, limb salvage, or survival estimate of 0 indicates that no patients a
rate is 0.
bA patency, limb salvage, or survival estimate of N/A indicates that no patien
so that the rate at the given time point is not estimable.
Fig 3. Three-year Kaplan-Meier estimates for primary,
underwent lower extremity (LE) reconstructions.(CCA)-vertebral bypass was patent at 5 months. A compar- gson of patency rates with log-rank between the various
ndication groups was not valid due to the small number of
vents.
Patients who underwent therapeutic interventions for
ondary patency Limb salvage Survival
0 (100-100) 97.3 (92.21-100) 97.6 (92.95-100)
.1 (91.54-100) 93.6 (85.18-100) 86.0 (75.3-98.3)
.0 (74.29-100) 93.6 (85.18-100) 86.0 (75.3-98.3)
0 (100-100) 96.2 (89.04-100) 96.7 (90.45-100)
0 (100-100) 90.5 (78.55-100) 84.0 (70.52-99.98)
0 (100-100) 90.5 (78.55-100) 84.0 (70.52-99.98)
0 (100-100) 100 (100-100) 100 (100-100)
.0 (42.59-100) 100 (100-100) 100 (100-100)
.0 (18.77-100) 100 (100-100) 100 (100-100)
0 (100-100) 100 (100-100) 100 (100-100)
0 (100-100) 100 (100-100) 83.3 (58.27-100)
0 (100-100) 100 (100-100) 83.3 (58.27-100)
0 (100-100) 100 (100-100) 100 (100-100)
N/Ab N/Ab 100 (100-100)
N/A N/A N/A
sk at the time point and that the last patient followed failed, so that the final
t risk at the time point and that the last patient being followed was censored,
ted primary, and secondary patencies for patients whoSec
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May 20121360 Brahmanandam et aldures. One LE reconstruction, one fistula, and one venous
reconstruction required balloon angioplasty for vein graft
stenosis found on surveillance. In the first two cases,
angioplasty was sufficient; these patients required no fur-
ther interventions to maintain patency. The venous recon-
struction required placement of a self-expanding stent in
addition to angioplasty for complete resolution of the
stenosis. In terms of operative procedures, one LE patient
underwent thrombectomy of the graft and one fistula pa-
tient required a patch angioplasty revision. The details of
the intervention for the LE patient are mentioned above in
the Results section. The fistula patient underwent patch
angioplasty with a bovine pericardial patch. The graft re-
mained patent after this operative intervention.
Overall limb salvage rates at 30 days, 1 year, and 3 years
were 97.3% (95% CI, 92.21-100), 93.6% (95% CI, 85.18-
100), and 93.6% (95% CI, 85.18-100), respectively. For
patients who underwent LE procedures, limb salvage rates
at 30 days, 1 year, and 3 years were 96.2% (95% CI,
89.04-100), 90.5% (95% CI, 78.55-100), and 90.5% (95%
CI, 78.55-100), respectively. For patients who underwent
all other types of procedures, limb salvage rates were 100%
at 1 month, 1 year, and 3 years (Table IV).
Overall survival rates at 30 days, 1 year, and 3 years were
97.6% (95% CI, 92.95-100), 86.0% (95% CI, 75.3-98.3),
and 86.0% (95% CI, 75.3-98.3), respectively. For patients
who underwent LE procedures, survival rates at 30 days, 1
year, and 3 years were 96.7% (95% CI, 90.45-100), 84.0%
(95% CI, 70.52-99.98), and 84.0% (95% CI, 70.52-
99.98), respectively. For patients who underwent fistula
creation, survival rates at 30 days, 1 year, and 3 years were
100.0% (95% CI, 100-100), 83.33% (95% CI, 58.27-100),
and 83.33% (95% CI, 58.27-100), respectively. Patients
who underwent venous procedures and the CCA-vertebral
bypass all had 100% survival rates 1 month, 1 year, and 3
years (Table IV). Follow-up of the study group ranged
from 1month to 8.7 years (mean time, 21months 28.2).
Twenty-one patients were followed for a period 6
months. Seven deaths occurred over 8.7 years. Five of these
deaths occurred within the first year andwere due to cardiac
arrest (one), congestive heart failure exacerbation (one),
multisystem organ failure from a previously infected graft
(one), and two of unknown causes. The other two patients
died at 5 years (cause unknown) and 8 years (complete
heart block) postsurgery. All patients had patent SFV grafts
at the time of their death.
DISCUSSION
Our series has shown that the SFV can be a versatile
conduit for both arterial and venous reconstructions when
the GSV is unavailable or of poor quality. Although our
results corroborate and expand on existing literature, we
intended to also demonstrate some unconventional uses of
the SFV that have rarely been studied. Some of the earliest
evidence supporting the use of SFV came from three studies
conducted by Schulman et al.1-3 They focused on the use of
SFV for femoral-popliteal bypass grafts. The main tenets
guiding their operative technique included profunda vein ireservation and short, single-segment conduits.1 They
ound that a conduit with a diameter 1.2 cm produced
etter long-term outcomes.1 The cumulative graft patency
ate was 70% over 3 years; additionally, they had no late
tructural changes of their grafts, and minimal venous
orbidity.2 Benjamin et al7 performed an analysis on using
FVs for patients with mycotic pseudoaneurysms. Five
atients underwent iliofemoral bypasses using SFV. All
ere patent at 20 months, with no amputations and no
enous morbidity. Ehsan and Gibbons,11 Dorweiler et al,12
nd Meneghetti et al13 all had positive experiences using
FVs for cross-pelvic femoral-femoral bypasses. All three
tudies demonstrated patent grafts at the end of their
espective follow-up periods and no amputations. Me-
eghetti et al13 had the larger series where 20 patients
nderwent cross-pelvic femoral-femoral bypasses with SFV
or either infected graft (12) or ischemia (eight). At the
onclusion of their study, all grafts were patent (follow-up
eriod of 6.25 years, mean of 24.3 months), and there was
o requirement for graft revision.
Our results for patients undergoing LE arterial recon-
tructions using SFV are comparable. At 3 years, our pri-
ary, assisted primary, and secondary patency rates were
8.3%, 100%, and 100%.Our limb salvage rate was 90.5% at
years. For LE reconstructions performed in a noninfected
eld, SFV was preferentially used over prosthetic grafts,
ecause these grafts have been more resistant to the devel-
pment of intimal hyperplasia in our experience. These
esults corroborate that the SFV is a reliable conduit for LE
rterial reconstructions, including iliofemoral and cross-
elvic femoral-femoral bypasses and femoral interposition
rafts, for varied indications.
The SFV graft has also proven to be an excellent
onduit for constructing LE AV fistulas when other con-
entional access sites have been exhausted. A meta-analysis
onducted by Antoniou et al14 looked at the outcomes of
FV transposition for AV fistulas as compared with upper-
high and midthigh AV grafts. Primary patency rates at 1
ear ranged from 73% to 93%; secondary patency rates at 1
ear ranged from 86% to 100%. These rates were higher
han those of either upper-thigh or midthigh AV grafts.
ne disadvantage noted, however, was the significantly
igher rate of ischemic complications due to steal when
sing an SFV graft (ranging from 0% to 33% of patients).
radman et al15 described tapering the SFV graft at the
akeoff from the distal femoral artery, as an operative tech-
ique that helped reduce ischemic complications.
Our experience with transposed SFV AV fistulas was
omparable to other groups, both in terms of patency and
schemic complications. At 3 years, our primary, assisted
rimary, and secondary patency rates were N/A, 100%, and
00%, respectively. Our limb savage rate was 100% at 3
ears as well. Only one patient suffered steal syndrome,
hich was corrected by performing a distal revasculariza-
ion and interval ligation procedure using a femoral above-
nee popliteal artery bypass. After this, she had no further
schemic symptoms and had a well-functioning fistula.
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formed with SFV. Hagino et al16 conducted a case series in
which four of their seven patients underwent such recon-
structions, including two innominate vein-to-right atrial
appendage bypasses; one internal jugular vein (IJV) inter-
position graft; and one axillary-to-IJV bypass. The indica-
tion for surgery in three patients was due to tumor that had
encased their deep central veins. One patient had a subcla-
vian stenosis due to a dialysis line, requiring an axillary-to-
IJV bypass. All bypasses were patent for their respective
courses of follow-up (2 weeks to 34 months), and none of
these patients suffered any venous morbidity.
We had four patients undergo central venous recon-
structions with SFV. Two patients underwent a subclavian-
to-innominate bypass. The indication for the first patient
was venous thoracic outlet syndrome; her graft occluded
after 5 years. The second patient underwent this due to
tumor encasement of the central veins; the graft required
both angioplasty and stenting of an extrinsic scar 2 months
postsurgery but remained patent for the entire 2.5 years of
follow-up. Two patients underwent their bypasses for SVC
syndrome. The patient who had undergone an axillary-to-
innominate bypass occluded his graft after 2.5 years and
could not be recanalized. The second patient, who had
undergone an innominate-to-SVC bypass, occluded within
1 month of its creation and could not be recanalized.
Although three grafts did ultimately occlude, the majority
of grafts remained patent for a comparable time period
ranging from 2.5 to 5 years.
Reconstruction of the innominate, common carotid,
and subclavian arteries has also been performed with SFV
for neurologic, ischemic, and aneurysmal symptoms.
Modrall et al17 followed 71 patients who had undergone
different combinations of these bypasses. Primary patency
was 92% at 4 years, and assisted primary patency was 100%.
Our series only had one patient, who underwent a CCA-
to-vertebral bypass for a stroke due to an occluded vertebral
artery. SFV was chosen as she had no suitable arm or leg
veins; the graft was a suitable size match as well. Her
neurologic symptoms improved, with no further sequelae.
This graft was followed for 5 months and was patent during
this entire period. Although our sample size is quite small,
the success of this reconstruction as well as the work by
Modrall et al17 warrants further investigation of the SFV as
an appropriate conduit for upper venous reconstructions.
The most common complication that occurred among
all patients in our series was wound complications. Those
who underwent LE procedures had the highest frequency
of wound complications (13; 41.9%). Only two of these
patients had serious wound complications; both had in-
fected lymphoceles requiring debridement and muscle
flaps. The remaining patients convalesced with conservative
management alone. None of these patients had an exposed
graft. Interestingly, nine of the 13 patients with wound
complications presented with infected grafts before sur-
gery, including the two patients with serious wound com-
plications. Although the majority of wound complications
did not involve infections, the initial presence of infection Aay have negatively affected wound healing. Not many
tudies delineated their experience with wound complica-
ions, so there are few available comparisons. Schulman et
l3 stated that 12.3% of their patients’ pool had lymphoce-
es and lymphorrhea but ultimately was of little clinical
ignificance.
Our series also demonstrated that SFV harvest could be
olerated with little venous morbidity. Wells et al18 con-
ucted a study specifically evaluating donor limbs after SFV
arvest. None of their patients suffered any chronic venous
hanges. Twenty-two percent of their patients did experi-
nce DVT, but the majority involved the popliteal vein
tump; these patients were not treated with anticoagula-
ion. Among our study group, only one patient had a
ostoperative DVT, which involved the popliteal vein and
alf veins. This patient was treated with anticoagulation and
onvalesced well. Venous duplex scans were not routinely
erformed in the postoperative period, unless symptoms
ere present. In our follow-up, no patients had any long-
erm venous morbidity, including leg edema, and/or ve-
ous claudication. It is certainly possible that there were
ilent DVTs; however, we did not see any clinical sequelae
n our patients. This may be because of our efforts to
reserve the GSV during harvest of the SFV.
The major limitations of this study would be the small
ize in two of the study groups and limited follow-up
ntervals in certain patients. We had small numbers of
atients in our venous and upper arterial bypass groups due
o the rarity of this pathology. The small n values limited us
rom performing complex statistical analyses to make
eaningful comparisons. Additionally, certain patients had
hort follow-up intervals because they were from out of
tate and continued their postoperative follow-up in their
ocal vicinity. This may have under- or overestimated the
ongevity of their graft patencies. Similarly, postoperative
omplications in patients lost to follow-up may have been
nderestimated because they were not reported in our
atabase. Finally, generalizations drawn from our pooled
nd venous estimates of patency, limb salvage, and survival
ust be drawn with the caveat that the study groups were
eterogeneous, as they included different types of recon-
tructions.
ONCLUSIONS
The SFV can be a versatile conduit for both arterial and
enous reconstructions when the GSV is unavailable or of
oor quality with excellent graft patency rates. Transposed
FV arteriovenous fistulas are another efficacious SFV re-
onstruction with excellent patency rates. SFV harvest is
ssociated with minimal venous morbidity in the donor
imb-making this a safe option. The only caveat is that
atients undergoing SFV reconstruction who present with
n infected graft may be at higher risk for developing a
ostoperative wound complication.
UTHOR CONTRIBUTIONS
onception and design: SB, TS, DC
nalysis and interpretation: SB, TS
11
1
1
1
1
1
1
1
JOURNAL OF VASCULAR SURGERY
May 20121362 Brahmanandam et alData collection: SB
Writing the article: SB, TS
Critical revision of the article: SB, TS
Final approval of the article: TS, DC
Statistical analysis: JB
Obtained funding: TS, DC
Overall responsibility: SB, TS
REFERENCES
1. SchulmanML, BadheyMR, Yatco R, Pillari G. A saphenous alternative:
preferential use of superficial femoral and popliteal veins as femoropop-
liteal bypass grafts. Am J Surg 1986;152:231-7.
2. Schulman ML, Badhey MR, Yatco R, Pillari G. An 11-year experience
with deep leg veins as femoropopliteal bypass grafts. Arch Surg 1986;
121:1010-5.
3. SchulmanML, BadheyMR, Yatco R. Superficial femoral-popliteal veins
and reversed saphenous veins as primary femoropopliteal bypass grafts:
a randomized comparative study. J Vasc Surg 1987;6:1-10.
4. Clagett GP, Valentine RJ, Hagino RT. Autogenous aortoiliac/femoral
reconstruction from superficial femoral-popliteal veins: feasibility and
durability. J Vasc Surg 1997;25:255-66; discussion 267-70.
5. ClagettGP, Bowers BL, Lopez-ViegoMA,RossiMB,ValentineRJ,Myers
SI, et al. Creation of a neo-aortoiliac system from lower extremity deep and
superficial veins. Ann Surg 1993;218:239-48; discussion 248-9.
6. CoburnM, Ashworth C, Francis W,Morin C, BroukhimM, CarneyWI
Jr. Venous stasis complications of the use of the superficial femoral and
popliteal veins for lower extremity bypass. J Vasc Surg 1993;17:1005-8;
discussion 1008-9.
7. Benjamin ME, Cohn EJ Jr, Purtill WA, Hanna DJ, Lilly MP, Flinn WR.
Arterial reconstruction with deep leg veins for the treatment of mycotic
aneurysms. J Vasc Surg 1999;30:1004-15.
8. Schanzer H, Chiang K, Mabrouk M, Peirce EC 2nd. Use of lower
extremity deep veins as arterial substitutes: functional status of the
donor leg. J Vasc Surg 1991;14:624-7. S9. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et
al. Recommended standards for reports dealing with lower extremity
ischemia: revised version. J Vasc Surg 1997;26:517-38.
0. Jackson, MR. The superficial femoral-popliteal vein transposition fis-
tula: description of a new vascular access procedure. J Am Coll Surg
2000;191:581-4.
1. Ehsan O, Gibbons CP. A 10-year experience of using femoro-popliteal
vein for re-vascularisation in graft and arterial infections. Eur J Vasc
Endovasc Surg 2009;38:172-9.
2. Dorweiler B, Neufang A, Schmiedt W, Oelert H. Autogenous recon-
struction of infected arterial prosthetic grafts utilizing the superficial
femoral vein. Thorac Cardiovasc Surg 2001;49:107-11.
3. Meneghetti AT, MacDonald PS, Reid JD, Sladen JG, Turnbull RG.
Patency of superficial femoral vein employed as a crossover femoral
artery bypass conduit. Ann Vasc Surg 2002;16:746-50.
4. AntoniouGA, LazaridesMK, Georgiadis GS, Sfyroeras GS, Nikolopou-
los ES, Giannoukas AD. Lower-extremity arteriovenous access for
haemodialysis: a systematic review. Eur J Vasc Endovasc Surg 2009;38:
365-72.
5. Gradman WS, Laub J, Cohen W. Femoral vein transposition for arte-
riovenous hemodialysis access: improved patient selection and intraop-
erative measures reduce postoperative ischemia. J Vasc Surg 2005;41:
279-84.
6. Hagino RT, Bengtson TD, Fosdick DA, Valentine RJ, Clagett GP.
Venous reconstructions using the superficial femoral-popliteal vein. J
Vasc Surg 1997;26:829-37.
7. Modrall JG, Joiner DR, Seidel SA, Jackson MR, Valentine RJ, Clagett
GP. Superficial femoral-popliteal vein as a conduit for brachiocephalic
arterial reconstructions. Ann Vasc Surg 2002;16:17-23.
8. Wells JK, Hagino RT, Bargmann KM, Jackson MR, Valentine RJ,
Kakish HB, et al. Venous morbidity after superficial femoral-popliteal
vein harvest. J Vasc Surg 1999;29:282-91.ubmitted Sep 28, 2011; accepted Nov 22, 2011.
